327 related articles for article (PubMed ID: 27143857)
1. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study.
Guerriero F; Roberto A; Greco MT; Sgarlata C; Rollone M; Corli O
Drug Des Devel Ther; 2016; 10():1515-23. PubMed ID: 27143857
[TBL] [Abstract][Full Text] [Related]
2. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients.
Guerriero F; Sgarlata C; Marcassa C; Ricevuti G; Rollone M
Clin Interv Aging; 2015; 10():1-11. PubMed ID: 25565782
[TBL] [Abstract][Full Text] [Related]
4. High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain.
Amato F; Ceniti S; Mameli S; Pisanu GM; Vellucci R; Palmieri V; Consoletti L; Magaldi D; Notaro P; Marcassa C
Support Care Cancer; 2017 Oct; 25(10):3051-3058. PubMed ID: 28470370
[TBL] [Abstract][Full Text] [Related]
5. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
[TBL] [Abstract][Full Text] [Related]
6. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
[TBL] [Abstract][Full Text] [Related]
8. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.
Poelaert J; Koopmans-Klein G; Dioh A; Louis F; Gorissen M; Logé D; Van Op den Bosch J; van Megen YJ
Clin Ther; 2015 Apr; 37(4):784-92. PubMed ID: 25757607
[TBL] [Abstract][Full Text] [Related]
9. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials.
Blagden M; Hafer J; Duerr H; Hopp M; Bosse B
Neurogastroenterol Motil; 2014 Dec; 26(12):1792-801. PubMed ID: 25346155
[TBL] [Abstract][Full Text] [Related]
10. Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment.
Koopmans-Klein G; Van Op den Bosch J; van Megen Y; Prenen H; Huygen F; Mancini I
Curr Med Res Opin; 2017 Dec; 33(12):2217-2227. PubMed ID: 28805471
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
Ueberall MA; Mueller-Schwefe GH
Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain.
Madeo G; Schirinzi T; Natoli S; Pierantozzi M; Stefani A; Dauri M; Pisani A
J Neurol; 2015 Sep; 262(9):2164-70. PubMed ID: 26134157
[TBL] [Abstract][Full Text] [Related]
13. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives.
Koopmans G; Simpson K; De Andrés J; Lux EA; Wagemans M; Van Megen Y
Curr Med Res Opin; 2014 Nov; 30(11):2389-96. PubMed ID: 25265132
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
[TBL] [Abstract][Full Text] [Related]
15. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
[TBL] [Abstract][Full Text] [Related]
16. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
Löwenstein O; Leyendecker P; Hopp M; Schutter U; Rogers PD; Uhl R; Bond S; Kremers W; Nichols T; Krain B; Reimer K
Expert Opin Pharmacother; 2009 Mar; 10(4):531-43. PubMed ID: 19243306
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.
Ahmedzai SH; Leppert W; Janecki M; Pakosz A; Lomax M; Duerr H; Hopp M
Support Care Cancer; 2015 Mar; 23(3):823-30. PubMed ID: 25218610
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.
Ahmedzai SH; Nauck F; Bar-Sela G; Bosse B; Leyendecker P; Hopp M
Palliat Med; 2012 Jan; 26(1):50-60. PubMed ID: 21937568
[TBL] [Abstract][Full Text] [Related]
19. Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Huang L; Zhou JG; Zhang Y; Wang F; Wang Y; Liu DH; Li XJ; Lv SP; Jin SH; Bai YJ; Ma H
J Pain Symptom Manage; 2017 Nov; 54(5):737-748.e3. PubMed ID: 28736104
[TBL] [Abstract][Full Text] [Related]
20. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
